These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25880539)

  • 1. A metabolomic approach to identifying platinum resistance in ovarian cancer.
    Poisson LM; Munkarah A; Madi H; Datta I; Hensley-Alford S; Tebbe C; Buekers T; Giri S; Rattan R
    J Ovarian Res; 2015 Mar; 8():13. PubMed ID: 25880539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
    Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.
    Hahne JC; Honig A; Meyer SR; Gambaryan S; Walter U; Wischhusen J; Häussler SF; Segerer SE; Fujita N; Dietl J; Engel JB
    Oncol Rep; 2012 Dec; 28(6):2023-8. PubMed ID: 22992944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer.
    Chappell NP; Teng PN; Hood BL; Wang G; Darcy KM; Hamilton CA; Maxwell GL; Conrads TP
    J Proteome Res; 2012 Sep; 11(9):4605-14. PubMed ID: 22900918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
    Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
    Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
    Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
    Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells.
    Varma R; Hector S; Greco WR; Clark K; Hawthorn L; Porter C; Pendyala L
    Cancer Chemother Pharmacol; 2007 May; 59(6):711-23. PubMed ID: 17021820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
    Deqnah N; Yu JQ; Beale P; Fisher K; Huq F
    Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
    Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
    Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antitumour activity of a new trinuclear platinum compound [{cis-PtCl(NH3)2μ {trans-Pt(3-hydroxypyridine)2H2N(CH2)5NH2)2}] Cl4 in human ovarian cancer cells.
    Hamad SA; Beale P; Yu JQ; Huq F
    Anticancer Res; 2014 Apr; 34(4):1923-9. PubMed ID: 24692727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
    Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
    Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic signatures differentiate ovarian from colon cancer cell lines.
    Halama A; Guerrouahen BS; Pasquier J; Diboun I; Karoly ED; Suhre K; Rafii A
    J Transl Med; 2015 Jul; 13():223. PubMed ID: 26169745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative 2D-DIGE proteomic analysis of ovarian carcinoma cells: toward a reorientation of biosynthesis pathways associated with acquired platinum resistance.
    Lincet H; Guével B; Pineau C; Allouche S; Lemoisson E; Poulain L; Gauduchon P
    J Proteomics; 2012 Feb; 75(4):1157-69. PubMed ID: 22100381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells.
    Britten RA; Hardy C; Vlahou A; Gregory B; Giri PS; Drake R
    Oncol Rep; 2005 Nov; 14(5):1323-30. PubMed ID: 16211304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
    Shellard SA; Hosking LK; Hill BT
    Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines.
    Dai Z; Yin J; He H; Li W; Hou C; Qian X; Mao N; Pan L
    Proteomics; 2010 Nov; 10(21):3789-99. PubMed ID: 20957754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.